Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2700324 | 1.00 | CYP2A6 (0.60) | CYP2A6ALDH1A1CYP1A2CYP3A4CA1 | |
| SCHEMBL28713840 | 0.85 | SMN1; SMN2 (0.50) | CYP2A6ALDH1A1CYP1A2CYP3A4CA1 | |
| SCHEMBL29419996 | 0.85 | SMN1; SMN2 (0.50) | CYP2A6ALDH1A1CYP1A2CYP3A4CA1 | |
| SCHEMBL28186476 | 0.83 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP1A2CYP3A4CA1 | |
| SCHEMBL28612539 | 0.83 | MGLL (0.46) | CYP2A6ALDH1A1CYP1A2CYP3A4CA1 | |
| SCHEMBL29419997 | 0.83 | CA1 (0.53) | CYP2A6ALDH1A1CYP1A2CYP3A4CA1 | |
| SCHEMBL28715755 | 0.83 | CA1 (0.53) | CYP2A6ALDH1A1CYP1A2CYP3A4CA1 | |
| SCHEMBL24534338 | 0.82 | CYP2A6 (0.88) | CYP2A6ALDH1A1CYP1A2CYP3A4CA1 | |
| SCHEMBL29360677 | 0.82 | CYP2A6 (0.88) | CYP2A6ALDH1A1CYP1A2CYP3A4CA1 | |
| SCHEMBL13907273 | 0.82 | CYP2A6 (0.88) | CYP2A6ALDH1A1CYP1A2CYP3A4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249685-A | Ortho-diaryl substituted phenanthrene or phenanthroline carrier transport material and preparation method and application thereof | 华南理工大学 | 2022-03-29 | — | — | CN | claimed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20250234703-A1 | Organic Compound And Organic Light-Emitting Element Comprising Same | P&H TECH CO., LTD (KR) | 2025-07-17 | — | — | US | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| CN-113195482-B | Compound having benzoxazole ring structure and organic electroluminescent element | 保土谷化学工业株式会社 | 2024-12-20 | — | — | CN | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-112805845-B | Compound having azabenzoxazole ring structure and organic electroluminescent element | 保土谷化学工业株式会社 | 2024-10-25 | — | — | CN | disclosed |
| CN-116354897-B | Substituted 1,2, 4-triazole, pyridine and pyrimidine derivatives and application thereof in medicines | 华东师范大学 | 2024-10-15 | — | — | CN | disclosed |
| CN-113200923-B | Compound for organic photoelectric device, composition for organic photoelectric device, and display device | 三星SDI株式会社 | 2024-09-13 | — | — | CN | disclosed |
| CN-113861188-B | Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor | 杭州医学院 | 2023-02-28 | — | — | CN | disclosed |
| CN-115536633-A | Compound and organic electroluminescent element comprising same | 索路思高新材料有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-107540620-B | Compound for organic photoelectric device, composition for organic photoelectric device, and display device | 三星SDI株式会社 | 2022-10-18 | — | — | CN | disclosed |
| CN-115103709-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-109790129-B | Pyrene triazine derivative and application thereof in organic electronic device | 广州华睿光电材料有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-110431680-B | Organic electroluminescent element | 保土谷化学工业株式会社 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022138107-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | 出光興産株式会社 | 2022-06-30 | — | — | WO | disclosed |
| CN-114555566-A | Organic compound and organic electroluminescent element comprising same | 索路思高新材料有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114249685-A | Ortho-diaryl substituted phenanthrene or phenanthroline carrier transport material and preparation method and application thereof | 华南理工大学 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250234703-A1 | Organic Compound And Organic Light-Emitting Element Comprising Same | CRY2, CRY1, RBP4 | CYP2A6 2454/4885ALDH1A1 584/4885CYP1A2 1101/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | CYP2A6 3954/4885ALDH1A1 3684/4885CYP1A2 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.